RayKnowChina Research Map
Shortlist0

Nanjing University

南京大学

NanjingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.08%Leads under 1 in 100 of China's research papers on NPC

Led 2 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025
ThemesImmunotherapy

Hospitals counted here

  1. Nanjing Drum Tower Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. The prognostic value of before treatment neutrophil-to-lymphocyte ratio in nasopharyngeal carcinoma.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  2. A bibliometric study of the nasopharyngeal cancer immunotherapy knowledge map.2024MedicineFree full text
Trials on ClinicalTrials.gov1
  1. PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesStatus unknownNCT03044743Lead sponsorPhase 1/Phase 2Start 2017-04

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.9%Leads under 1 in 100 of China's research papers on ESCC

Led 26 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
26
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesMolecular markers & genomicsSurgeryImaging & AI

Hospitals counted here

  1. Nanjing Drum Tower Hospital13
  2. Jinling Hospital9
  3. Affiliated Hospital of Nanjing University Counted in the group total2
  4. Suzhou Hospital Counted in the group total1
  5. Affiliated Yancheng First Hospital of Nanjing University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Comparison of clinical and prognostic characteristics between superficial basaloid and conventional esophageal squamous carcinoma.2026Esophagus : official journal of the Japan Esophageal Society
  2. Predicting Postoperative Recurrence Using a Support Vector Machine for Patients With Esophageal Squamous Cell Carcinoma: Machine Learning Modeling Development and Validation Study.2025JMIR cancerFree full text
  3. Retrospective Analysis of Risk Factors and Prediction Model of Cervical Anastomotic and Intrathoracic Anastomotic Leakage After Radical Esophagectomy.2025Cancer reports (Hoboken, N.J.)Free full text
  4. Incidence of MSI-H esophageal carcinoma and related identification of genomic alterations: A multi-center real-world study.2025Human pathology
  5. Effects of immunoenteric nutrition versus general enteral nutrition on prognosis in patients with squamous cell carcinoma undergoing radical esophagectomy post neoadjuvant chemotherapy.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
Trials on ClinicalTrials.gov4
  1. Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04644250Lead sponsorPhase 2Start 2020-09
  2. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  3. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  4. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.9%Leads under 1 in 100 of China's research papers on HCC

Led 137 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
3
Research papers it led
137
Trials it led
10
Share of China's trials
0.7%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 222025
ThemesImmunotherapy & targeted drugsRecurrence & prognosisHepatitis B & cirrhosis

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Nanjing Drum Tower Hospital95
  2. Jinling Hospital23
  3. Affiliated Hospital of Nanjing University Counted in the group total6
  4. Gulou Hospital1
  5. Affiliated Yancheng First Hospital of Nanjing University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  2. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.2023Lancet (London, England)RCT
  3. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.2023Lancet (London, England)RCT
  4. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.2025The Lancet. OncologyRCT
  5. Differential HCC risk among HBV indeterminate types at baseline and by phase transition.2025Gut
Trials on ClinicalTrials.gov6
  1. FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07314372Lead sponsorPhase 2Start 2026-02
  2. Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCCRecruitingNCT07769827Lead sponsorN/AStart 2025-12
  3. Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate PhaseRecruitingNCT05661786Lead sponsorStart 2022-12
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  5. The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After HepatectomyStatus unknownNCT06278701Lead sponsorN/AStart 2023-11
  6. Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal ImageStatus unknownNCT05627297Lead sponsorStart 2022-12

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.5%Leads about 1 in 68 of China's research papers on Stomach cancer

Led 145 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
4
Research papers it led
145
Trials it led
18
Share of China's trials
1.2%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 112025
ThemesSurgeryImmunotherapy & targeted drugsPeritoneal spread & advanced disease

Hospitals counted here

  1. Nanjing Drum Tower Hospital113
  2. Jinling Hospital20
  3. Suzhou Hospital Counted in the group total2
  4. Affiliated Hospital of Nanjing University Counted in the group total2
  5. Nanjing Stomatological Hospital Counted in the group total1
  6. Jining Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Efficacy and safety of subserosal versus submucosal carbon nanoparticle-guided laparoscopic radical gastrectomy (DANCE-04): A randomized clinical trial.2026SurgeryRCT
  2. Novel tetrameric bispecific KK-LC-1×CD16A-armed memory-like NK cells enhance antitumor efficacy in gastric cancer.2025Journal for immunotherapy of cancerFree full text
  3. NNMT enriches for AQP5+ cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma.2023Gut
  4. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.2021Journal for immunotherapy of cancerFree full text
  5. Esophagojejunostomy using a circular stapler after laparoscopic total gastrectomy with pouch suture and multifunctional sealing cap: a simple, safe, and effective anastomosis technique.2026Updates in surgery
Trials on ClinicalTrials.gov6
  1. A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric CancerNot yet recruitingNCT07615907Lead sponsorN/AStart 2026-05
  2. Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric CancerRecruitingNCT07298200Lead sponsorPhase 1Start 2025-12
  3. Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ CancerRecruitingNCT06791148Lead sponsorPhase 2Start 2024-07
  4. Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ AdenocarcinomaRecruitingNCT05687357Lead sponsorPhase 2Start 2023-03
  5. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  6. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.0%Leads none of China's research papers on Retinoblastoma

Led 0 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.0%Leads about 1 in 98 of China's research papers on Osteosarcoma

Led 23 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
23
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Jinling Hospital14
  2. Nanjing Drum Tower Hospital8
  3. Yancheng First Hospital, Nanjing University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
2.5%Leads about 1 in 40 of China's research papers on Gastrointestinal stromal tumour

Led 13 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
2
Share of China's trials
2.7%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 4420232024: 1120242025: 002025

Hospitals counted here

  1. Nanjing Drum Tower Hospital12
  2. Affiliated Hospital of Nanjing University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.2%Leads under 1 in 100 of China's research papers on Neuroblastoma New since 2021

Led 2 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Nanjing Drum Tower Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.2%Leads about 1 in 80 of China's research papers on Myeloma ▼ from 1.8%

Led 21 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
1
Research papers it led
21
Trials it led
4
Share of China's trials
0.8%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 112025
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance

Hospitals counted here

  1. Nanjing Drum Tower Hospital17
  2. Jinling Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Licochalcone A suppresses Sp1 expression with potential anti-myeloma activity.2021Cancer communications (London, England)Free full text
  2. Clinicopathological characteristics of light chain proximal tubulopathy: a multicentre case series.2025Journal of clinical pathology
  3. Leveraging diverse cellular stress patterns for predicting clinical outcomes and therapeutic responses in patients with multiple myeloma.2024Journal of cellular and molecular medicineFree full text
  4. Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients.2024Hematology (Amsterdam, Netherlands)
  5. DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.2021Carcinogenesis
Trials on ClinicalTrials.gov6
  1. Autologous Stem Cell Transplantation for Patients With AL AmyloidosisEnrolling by invitationNCT04210791Lead sponsorStart 2010-07
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  3. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  5. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  6. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.5%Leads under 1 in 100 of China's research papers on HLH ▼ from 1.1%

Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025
ThemesTreatment regimensLymphoma & cancer-related HLH

Hospitals counted here

  1. Nanjing Drum Tower Hospital Counted in the group total1
  2. Jinling Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.7%Leads under 1 in 100 of China's research papers on Haemophilia A

Led 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Nanjing Drum Tower Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.2%Leads under 1 in 100 of China's research papers on NMOSD

Led 1 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. People's Hospital, Nanjing University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
0.4%Leads under 1 in 100 of China's research papers on IgG4-RD ▼ from 1.5%

Led 1 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
1
Research papers it led
1
Trials it led
1
Share of China's trials
2.3%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Nanjing Stomatological Hospital, Nanjing University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.4%Leads under 1 in 100 of China's research papers on Myasthenia gravis

Led 2 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025
ThemesThymus & thymectomyBiologic & complement drugs

Hospitals counted here

  1. Nanjing Drum Tower Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
2.0%Leads about 1 in 51 of China's research papers on Moyamoya ▲ from 1.3%

Led 7 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesImaging & blood flowRevascularisation surgeryChildren

Hospitals counted here

  1. Nanjing Drum Tower Hospital7

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
4.3%Leads about 1 in 23 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 11.8%

Led 43 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
43
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Nanjing Drum Tower Hospital31
  2. Jinling Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Air pollution exposure modes, smoking and genetic risk with chronic respiratory diseases: a prospective study.2025NPJ primary care respiratory medicine
  2. Serum cholesterol levels predict the survival in patients with idiopathic pulmonary fibrosis: A long-term follow up study.2025Respiratory medicine
  3. The potential lipid biomarker 5-HETE for acute exacerbation identified by metabolomics in patients with idiopathic pulmonary fibrosis.2025Respirology (Carlton, Vic.)
  4. Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.2024The European respiratory journal
  5. Diagnostic finding on high-resolution computed tomography (HRCT) predicts a good response to pirfenidone in patients with idiopathic pulmonary fibrosis.2023Medicine
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.3%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis New since 2021

Led 2 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.03%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Jinling Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
8.6%Leads about 1 in 12 of China's research papers on Alport syndrome

Led 5 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
1.4%
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Jinling Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.8%Leads about 1 in 56 of China's research papers on IgA nephropathy ▼ from 2.4%

Led 13 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
2
Share of China's trials
1.7%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 002025

Hospitals counted here

  1. Jinling Hospital10
  2. Nanjing Drum Tower Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.0%Leads about 1 in 100 of China's research papers on Primary biliary cholangitis ▼ from 2.0%

Led 3 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Second Hospital, Nanjing University1
  2. Nanjing Drum Tower Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov